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Summary and Key Words 
The historical development of different techniques for the study of 
proliferative patterns of normal and malignant tissue is explained. For 
more than 100 years, pathologists and clinicians have attempted to 
clarify the prognostic impact of this tumor-biological parameter. One 
relevant result of these investigations is the 'Grading-System', a 
histomorphological description of tumor cell differentiation. The auto-
radiographic method using tritiated thymidine (thymidine incorpora-
tion assay) detects a portion of DNA-sythesizing cells directly. How-
ever, radioactivity and long autoradiographic exposure times are the 
main disadvantages. D N A cytophotometry and immunohistochemical 
labeling are currently the most frequently used techniques for direct 
assessment of proliferating cells in normal and malignant renal tissue 
as well as in other human tumor tissues. Concerning renal cell car-
cinoma (RCC). our own experience and the results of the literature 
are compared and discussed: In contrast to tumor staging, tumor 
grading correlates with the tumor-specific proliferation rates. Accord-
ing to the present data, the measurement of the proliferative kinetics 
seems to be a relevant prognostic parameter for detection of high-risk 
patients, especially in the early stages showing identical histological 
findings for staging and grading. 
Renal cell carcinoma · Proliferation kinetics · Autoradiographic techni-
que · DNA-cytometry · Immunostaining 
Zusammenfassung und Schlüsselwörter 
Die Entwicklung der verschiedenen Techniken zur Erfassung des 
proliferativen Verhaltens von Normal- und Tumorgewebe beim Nie-
renzell-Karzinom wird beschrieben. Seit mehr als 100 Jahren beschäf-
tigen sich Pathologen und Kliniker mit der prognostischen Relevanz 
dieses tumor-biologischen Parameters. Ein Ergebnis dieser Forschung 
ist das «Grading-System», eine histomorphologische Beschreibung der 
Tumorzell-Differenzierung. Die autoradiographische Methode unter 
Verwendung von radiomarkiertem Thymidin (Thymidineinbaurate) 
erfaßt direkt die Rate der DNA-synthetisierenden Zellen. Radioakti-
vität und lange Expositionszeiten sind die Hauptnachteile dieser 
Methode. Die DNA-Zytophotometrie sowie immunhistochemische 
Markierungsmethoden sind gegenwärtig die am häufigsten angewand-
ten Methoden zur direkten Bestimmung des Anteils proliferierender 
Zellen sowohl im Normal- als auch im Tumorgewebe der Niere sowie 
auch anderer Tumoren des Menschen. Die eigenen Erfahrungen sowie 
die Ergebnisse verschiedener Autoren werden verglichen und disku-
tiert: Im Gegensatz zum Tumor-Staging zeigt das Tumor-Grading eine 
Korrelation gegenüber den tumor-spezifischen Proliferationsraten. 
G e m ä ß den Daten aus der Literatur erscheint die Bestimmung der 
tumor-spezifischen Proliferationskinetik als ein relevanter prognosti-
scher Faktor zur Erfassung von Hoch-Risiko-Patienten, insbesondere 
in Frühstadien mit identischen histologischen Befunden im Staging 
und Grading 
Nierenzellkarzinom • Proliferationskinetik · Autoradiographische Tech-
nik · DNS-Zytometrie · Immunhistochemie 
Historical Survey 
One of the main characteristics of cancer is the haphazard 
proliferation of malignant cells. The fraction of proliferating 
cells strongly influences tumor growth and is believed to be a 
major parameter for prognosis and treatment selection [ 1 , 2], 
For more than 100 years pathologists and clinicians have been 
engaged in examining proliferative patterns and behavior of 
human malignancies, comparing these results with normal 
tissue findings. This is necessary for a better understanding of 
pathogenesis, therapeutic principles and individual prognosis. 
Flamming (1882) and Waldeyer (1888) were the first to de-
scribe the histomorphological conception of 'cell division, 
mitosis and cell proliferation' in human malignancies [3]. In 
different malignant tumors, pathologists found a correlation 
between the mitosis rate determined in histological specimens 
and individual clinical course of patients with neoplasms [2, 4]. 
Mitosis, however, represents only a short phase in the active 
cell cycle. Microscopically, only 1% - 5% of all DNA-synthe-
sizing cells are detectable in histological specimens [5, 6, 7]. 
Therefore, this can only be regarded as an indirect parameter 
of the proliferative pattern of the tissue. 
It took a long time before a technique for the direct detection 
of tumor specific proliferation rates was made available. By 
autoradiographic studies using tritiated thymidine ( [ 3 H]-Thd) 
(=thymidine incorporation assay), direct measurement of the 
portion of DNA-synthesizing cells was achieved for the first 
time. In 1979, Rabes et al. [5] presented a clinical report of 
proliferation rates in renal cell carcinoma (RCC) using this 
technique. The authors found low proliferation rates (<20%) 
and a correlation to the recurrence rate in a series of RCC 
patients. The main disadvantages of this method, however, 
involve the extracorporal organ perfusion (ex vivo) required 
after tumor nephrectomy, the radioactive contamination and 
waste disposal as well as personal safety, long autoradiogra-
phic exposure times and, thus, the lack of practicability of this 
technique in routine diagnosis [6, 8]. The successful immuno-
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logical preparation of monoclonal antibodies represented a 
relevant advance in this field [9]. 
DNA-Cytometry for R C C 
Single-cell and flow DNA-cyto(photo)metry (e.g. combined 
with the Feulgen staining) are commonly used techniques for 
the evaluation DNA-content of malignant of tissue tumors [2]. 
Formalin-fixed and paraffin-embedded tissue [10] as well as 
fresh tissue can be analyzed for DNA-cytophotometry [2]. 
This technique has been used for more than ten years in basic 
and clinical research. Extensive experience has been achieved 
by means of this technique: In 1985, Ljungberg was one of the 
first authors using D N A flow-cytometry on RCC [11]. In 196 
analysed tissue samples of 25 cases of RCC, a correlation 
between D N A distribution (ploidy) and morphologic grading 
was demonstrated. Tumor proliferation, as determined by the 
fraction of cells in S-phase, was significantly higher in aneu-
ploid samples compared to normal kidney tissue samples and 
diploid tumor samples. This paper was the first to describe 
D N A heterogeneity in RCC caused by different tumor cell 
clones. To exclude a so-called "sampling error' several biopsies 
depending on the tumor size must be taken from each tumor 
[11]. About 40% of the analyzed RCC were aneuploid with a 
D N A content > 5 C. Different studies confirmed the progno­
stic importance of this parameter in RCC [12, 13]. 
The results of both techniques, single-cell and flow D N A -
cytometry, showed no relevant differences in ploidy heteroge­
neity and prognostic value of D N A content for RCC patients 
[14]. 
The main disadvantage is that this technology requires equip­
ment for photometric imaging. Due to the expense this equip­
ment is only available in research and medical centers. A l ­
though it is a valid and reliable parameter in RCC, D N A -
cytometry did not prove successful in routine diagnostics [15]. 
Immunohistochemical Techniques 
Bromodeoxyuridine (BrdU) Technique 
In order to avoid the problems of the thymidine incorporation 
assay, several investigators used S-bromo^-deoxyuridine 
(BrdU), a non-radioactive thymidine analogue which is also 
incorporated into DNA-synthesizing cells [8 ,16,17,18,19] . In 
1982, Gratzner et al. isolated and described a monoclonal 
antibody (mab) against B r d U [20] which allows for the rapid 
detection of BrdU-laden cells in vivo and in vitro as well as 
by immunohistochemical techniques [21]. Although BrdU 
immunohistochemistry solves many of the problems associated 
with [ 3 H]-Thd in cell kinetics studies (as outlined above), its 
use generates the following problems: B r d U is a cytotoxic 
substance. Administrations of B r d U at high doses have been 
shown to be mutagenic in vitro and carcinogenic in vivo in an 
animal model [22]. B rdU also inhibits cell differentiation and 
thymidine uptake in vitro, as well as D N A synthesis and cell 
replication in both in vitro and in vivo settings [8]. Whether or 
not these negative aspects of B r d U administration affect the 
results compiled by in-vivo cell kinetic studies, remains un­
clear. Due to the mutagenic and carcinogenic potentials, B r d U 
can only be used for animal and in-vitro studies, but not for 
direct in-vivo determination of proliferative cell fractions in 
human malignancies. Therefore, the BrdU immunohistochem­
istry represents an indirect method only to assess the prolifera­
tion rates in human neoplasms. 
Ki-67 Staining 
In 1983, Gerdes et al. isolated and characterized a human 
nuclear antigen (termed kKi-67') present in DNA-synthesizing 
cells only [23]; its expression is observed in normal as well as in 
malignant cells but is absent in resting cells [24]. Figure 1 
illustrates this schematically for the different phases of cell 
division [24]. Using frozen sections and immunhistochemical 
staining techniques as outlined by Gerdes [25] and Cordell 
[26], individual in-vivo proliferation rates can now be obtained 
directly in normal and malignant tissue as well (fig. 2). 
Ki-67 is a mouse monoclonal antibody which binds to a human 
nuclear antigen associated with cell proliferation [23, 24]. Cell 
cycle analyses demonstrated that the nuclear antigen detected 
by Ki-67 is only expressed in the G{, S, G 2 and Μ phases of 
proliferating cells, normal as well as malignant, but is absent in 
resting cells (G 0 ) (fig. 1) [24, 25]. Immunostainings with Ki-67 
revealed nuclear reactivity in cells of germinal centres of 
cortical follicles, cortical thymocytes, neck cells of gastroin­
testinal mucosa, undifferentiated spermatogonia and cells of a 
number of human cell lines. The Ki-67 antibody did not react 
with cells known to be in a resting stage such as lymphocytes, 
monocytes, parietal cells and Panetlrs cells of gastrointestinal 
mucosa, hepatocytes, normal renal cells, mature sperm cells 
and brain cells [23]. Expression of this antigen recognized by 
Ki-67 could be induced in peripheral blood lymphocytes after 
G c ( Κ Ϊ 6 7 - ) 
G . . ( Κ Ϊ 6 7 - ) 
Fig. 1. Occurrence of cell proliferation-associated nuclear antigen 
(Ki-67) in the different phases of cell cycle [24]. -I- = antigen expres­
sion: - = no antigen expression. 
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Fig. 2. Immunochemical labeling of a proliferation-associated nuclear 
antigen using the mab Ki-67 and the alkaline phosphatase anti-alkaline 
phosphatase (APAAP) complex: Positive cells are stained red, hemal-
um is often used for counterstaining (—> blue). 
stimulation with phytohaemagglutinin, where as it disap­
peared from HL-60 cells stimulated with phorbol esters to 
differentiate into mature macrophages in the resting stage* [5]. 
In the meantime, numerous reports of immunohistochemical 
investigations on normal and malignant human tissues have 
confirmed die Ki-67 staining assay to be an easy, practicable, 
reliable and reproduceable method for evaluating the pro­
portion of proliferating cells (proliferation rates) [2, 27, 28, 29, 
30, 31]. 
Ki-67 staining is performed as follows: Tissue biopsies must be 
stored in fluid nitrogen to get 5μ frozen sections for the 
immunohisiochemical staining; formalin fixed samples are not 
suitable [25]. As recently described, growth fractions of cultur­
ed tumor cells can also be immunocytochemically determined 
on special slide chambers [15, 31]. 
Ki-67 staining is delineated schematically in figure 2: The 
acetone- and chloroform-fixed cells (in vivo: 5μ frozen sec­
tions; in vitro: eel's are directly attached on the slides [15]) are 
exposed for approximately 30 minutes to the monoclonal 
antibody (Ki-67) which has been diluted in R P M I 1640 me­
dium. Afier washing in TRIS-buffered solution (pH 7.4 - 7.6), 
the cells are incubated with rabbit-anti-mouse IgG and then 
exposed :o APAAP (alkaline phosphatase anti-alkaline pho­
sphatase) complex after repeated washing [26]. Subsequently, 
the slides are stained with 'Fast Red' and counter/stained with 
hemalum [25, 31]. Presence of the specific proliferation-asso­
ciated nuclear antigen is indicated by a red instead of a blue 
color reaction after counterstaining (fig. 3,4). 
Different human malignancies have already been investigated 
using the Ki-67 immunohistochemistry [1 ,2 , 15, 27, 29, 30, 32, 
33, 34, 35]: The in vivo proliferation rate of RCC is low, only 
ranging up to 25% [15, 36]. Because of this low proliferative 
potential, only a few mitotic cells can be obtained by biopsy. 
For that reason, direct karyotyping of the cells is impaired by 
irregular contractions of the chromosomes [37, 38, 39]. There­
fore, reports on the chromosomal features of RCC are rare. 
Yoshida et al [39] were among the first to karyotype malignant 
renal cells after short-term in vitro culturing. 
During short-term in vitro culturing, the proliferation rates of 
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• Γ. fr--* . 
Fig. 3. Immunhistochemical in vivo staining of an undifferentiated 
renal cell carcinoma using the Ki-67 technique. Positive cells are 
stained darkly. Proliferation rate (PR) = 15%; original magnification 
x 120. 
Fig. 4. In vitro short term cell culture of the same renal cell carcinoma 
as demonstrated in figure 3, immunocytochemical staining obtained 
using mab Ki-67, positive cells are stained darkly. PR = 82%; original 
magnification x 120. 
malignant renal cells increase up to 85%. This phenomenon 
improves the cytogenetical output [15]. Malignant renal cells 
prepared in vitro in the manner as recently described were 
characterized by employing conventional cytological, cytoche-
mical and immunocytochemical measures [40]: Malignant re­
nal cells were exclusively obtained by the cell-cluster prepara­
tion technique [7]. Aberrations on the short (p) arm of chro­
mosome 3 were the most common cytogenetic finding (77.8%) 
in 36 cases of non-familial RCC. I t seems that this chromoso­
mal defect is the initial cytogenetic change and that it triggers 
genetic instability during the clonal development and progres­
sion of human RCC [7, 15]. These connected findings could be 
appropriately verified by the described Ki-67 immunostaining 
assay [15]. 
There are different methods to determine the percentage of 
Ki-67-positive cells; one is described by Gerdes [25]. In recent 
years, the immunostaining quantitative analysis has been done 
by means of a computer-assisted image processor configured 
with a standard microscope [27]. The highest proliferation rate 
found for all specimens in a given case is considered to be 
representative of the entire tumor. To exclude sampling errors 
in the determination of the tumor-specific proliferation rate, 
several samples of solid tumor tissue must be obtained, depen­
ding on the individual tumor size (table 1) [15]. This experien­
ce is also described in other maligant soft tissue tumors, taking 
into account that several biopsies are necessary to obtain the 
intratumoral variability [27]. 
As illustrated in figure 5, fresh tumor tissue must be stored 
immediately in fluid nitrogen for correct and reliable determi­
nation of the tumor-specific proleferation rate [15]. Rates 
measured 3.5 h after tumor nephrectomy amounted to only 
approximately 50% of those initially determined [15]. This 
observation correlates with in vitro growth rates of tumor 
cells, which depend essentially on the interval between ne­
phrectomy, tissue sampling and fresh tissue preparation [40. 
41]. 
Tumor infiltrating lymphocytes often observed in the periphe­
ral zones of RCC should be excluded in the immunohistoche-
mical Ki-67 evaluation. These lymphcytes exhibit cell prolife­
ration within the tumor which are obviously caused by 
lymphokines and can therefore simulate higher proliferation 
rates of the tumor. For this reason, reference slides of each 
biopsy must be taken for conventional histological examina­
tion to exclude this phenomenon on frozen sections; histologi­
cal differentiation between lymphocytes and tumor cells is 
almost impossible on frozen sections alone [15]. 
Confirming the data published by Rabes et al. [5, 6], higher 
proliferation rates were always measured in the peripheral 
zones of the tumors as compared with central zones [15]. This 
is obviously nutrition-related due to better blood circulation in 
the peripheral areas. According to these findings, it is obvious 
that necroses and cysts initially develop in the central zones of 
renal tumors, a phenomenon often observed macroscopically 
[42]. 
Urological and other solid human malignancies exhibited simi­
lar proliferation rates (defined by the mab Ki-67) to those 
already mentioned for RCC [15, 36]: 
Transitional cell carcinomas of the bladder: 
Histological grade 1 tumors showed proliferation rates ranging 
between 1 % - 5 % , whereas grade 3 tumors yielded up to 30% 
[1]· 
Prostatic carcinoma: 
Low-grade tumors: l % - 3 % . High-grade tumors: 10% - 1 8 % 
[32]. 
Non-small cell lung cancer: 
Low-grade tumors: l % - 5 % . High-grade tumors: 15%-20% 
[27]. 
Table 1. Number of specimens according to tumor seize for represen­
tative measurement of PRs 
Peripheral (n) central (n) 
< 3 cm 2 1 
3-6 cm 4 2 
> 6 cm 6 2 
peripheral 
PR 
I > central 
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Fig. 5. In vivo proliferation rates plotted against the time of specimen 
collection (mean values of ten different tumors). 
Breast cancer: 
Low-grade tumors: 2 % - 1 2 % . High-grade tumors: 
13%-20% [28. 54, 35]. 
Up to now, only a few papers have dealt with the tumor-
specific Ki-67 determination in RCC [15, 36, 43, 44], revealing 
a correlation between proliferation rates and histological gra­
ding, but almost no correlation with tumor stage. 
The individual tumor stage cannot be concluded from the 
proliferation status, as it is a function of cell proliferation as 
well as of the time of tumor growth, the latter parameter not 
being measureable at the time of diagnosis. Some large RCC 
exhibited low proliferation rates, where as low-stage tumors 
(pT |_2 : 2-4cm in diameter) were found to vary 5-fold in 
proliferation rates [15]. These data explain the clinical obser­
vation in cases of RCC in which, despite a non-surgical ap­
proach for various reasons, an almost proliferative arrest was 
noted at long-term follow-up [45]. On the other side unusual 
growth rates of low-stage were observed by imaging techni­
ques (CT, sonography) [46, 47]. A similiar correlation is found 
in other malignancies using the Ki-67 immunohistochemistry 
revealing a correlation between proliferation status and tumor 
grading, but no correlation with tumor stage [2, 28, 34, 35]. 
Only a few authors have outlined the correlation of prolifera­
tive behavior of different malignancies and prognosis. Measu­
rement of the individual proliferation status appears to be an 
additional diagnostic parameter for the detection of RCC 
patients at high risk, especially in the early stages showing 
identical histological features [15, 36, 43, 44]. 
In breast cancer, the immunohistochemical Ki-67 parameter 
was found to be an additional independent prognostic parame­
ter beyond conventional histologial staging and grading [28, 
34]. Further investigations are necessary to study immunohi­
stochemistry and long-term follow-up of patients to confirm 
this preliminary experience. 
Comparative studies verified the equivalence of D N A cytome­
try and immunhistochemical Ki-67 index in assessing the proli­
ferative cell fraction of normal and malignant tissue [2]. Be­
cause immunohistochemical staining techniques are employed 
in almost all pathological institutions, the Ki-67 staining assay 
wil l , in the future, most probably be used for routine histologi­
cal diagnostics. Immunhistochemical determination of tumor-
specific proliferation rates using the monoclonal antibody 
(mab) K i -6 T is a practicable, reproducible and reliable method 
to obtain the proliferative pattern of RCC and other human 
malignancies. I t may be important for the detection of high-
risk patients and, conclusively, for prognosis. 
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